Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 9.04
CRDC's Cash to Debt is ranked higher than
69% of the 192 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.21 vs. CRDC: 9.04 )
Ranked among companies with meaningful Cash to Debt only.
CRDC' s 10-Year Cash to Debt Range
Min: 0.36  Med: 6.08 Max: No Debt
Current: 9.04
Equity to Asset 0.77
CRDC's Equity to Asset is ranked higher than
78% of the 181 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.60 vs. CRDC: 0.77 )
Ranked among companies with meaningful Equity to Asset only.
CRDC' s 10-Year Equity to Asset Range
Min: -5.64  Med: 0.68 Max: 0.86
Current: 0.77
-5.64
0.86
F-Score: 4
Z-Score: -6.36
M-Score: -2.39
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -590.56
CRDC's Operating margin (%) is ranked lower than
96% of the 189 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.48 vs. CRDC: -590.56 )
Ranked among companies with meaningful Operating margin (%) only.
CRDC' s 10-Year Operating margin (%) Range
Min: -1065.07  Med: -437.01 Max: -26.6
Current: -590.56
-1065.07
-26.6
Net-margin (%) -603.71
CRDC's Net-margin (%) is ranked lower than
97% of the 189 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.54 vs. CRDC: -603.71 )
Ranked among companies with meaningful Net-margin (%) only.
CRDC' s 10-Year Net-margin (%) Range
Min: -1281.1  Med: -384.87 Max: -26.56
Current: -603.71
-1281.1
-26.56
ROE (%) -83.47
CRDC's ROE (%) is ranked lower than
90% of the 182 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.29 vs. CRDC: -83.47 )
Ranked among companies with meaningful ROE (%) only.
CRDC' s 10-Year ROE (%) Range
Min: -171.5  Med: -104.08 Max: -45.86
Current: -83.47
-171.5
-45.86
ROA (%) -59.13
CRDC's ROA (%) is ranked lower than
91% of the 193 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.43 vs. CRDC: -59.13 )
Ranked among companies with meaningful ROA (%) only.
CRDC' s 10-Year ROA (%) Range
Min: -108.53  Med: -59.52 Max: -33.08
Current: -59.13
-108.53
-33.08
ROC (Joel Greenblatt) (%) -866.15
CRDC's ROC (Joel Greenblatt) (%) is ranked lower than
93% of the 191 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 11.56 vs. CRDC: -866.15 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
CRDC' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1119.89  Med: -743.37 Max: -341.72
Current: -866.15
-1119.89
-341.72
Revenue Growth (3Y)(%) -51.30
CRDC's Revenue Growth (3Y)(%) is ranked lower than
97% of the 151 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.00 vs. CRDC: -51.30 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
CRDC' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0  Med: -25.15 Max: 13.6
Current: -51.3
0
13.6
EBITDA Growth (3Y)(%) 33.20
CRDC's EBITDA Growth (3Y)(%) is ranked higher than
87% of the 128 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.70 vs. CRDC: 33.20 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
CRDC' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -54.9  Med: -28.00 Max: 33.2
Current: 33.2
-54.9
33.2
EPS Growth (3Y)(%) 31.70
CRDC's EPS Growth (3Y)(%) is ranked higher than
86% of the 126 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.70 vs. CRDC: 31.70 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
CRDC' s 10-Year EPS Growth (3Y)(%) Range
Min: -51.5  Med: -26.20 Max: 31.7
Current: 31.7
-51.5
31.7
» CRDC's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2014

CRDC Guru Trades in Q3 2014

PRIMECAP Management 5,864,500 sh (+0.37%)
Chuck Royce 54,486 sh (-52.41%)
» More
Q4 2014

CRDC Guru Trades in Q4 2014

PRIMECAP Management 6,013,500 sh (+2.54%)
Chuck Royce Sold Out
» More
Q1 2015

CRDC Guru Trades in Q1 2015

PRIMECAP Management 6,013,500 sh (unchged)
» More
Q2 2015

CRDC Guru Trades in Q2 2015

PRIMECAP Management 6,013,500 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with CRDC

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 3.77
CRDC's P/B is ranked lower than
60% of the 178 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.91 vs. CRDC: 3.77 )
Ranked among companies with meaningful P/B only.
CRDC' s 10-Year P/B Range
Min: 1.26  Med: 4.85 Max: 15.73
Current: 3.77
1.26
15.73
P/S 8.89
CRDC's P/S is ranked lower than
85% of the 190 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.67 vs. CRDC: 8.89 )
Ranked among companies with meaningful P/S only.
CRDC' s 10-Year P/S Range
Min: 1.54  Med: 13.75 Max: 35.68
Current: 8.89
1.54
35.68
Current Ratio 10.02
CRDC's Current Ratio is ranked higher than
95% of the 185 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.41 vs. CRDC: 10.02 )
Ranked among companies with meaningful Current Ratio only.
CRDC' s 10-Year Current Ratio Range
Min: 1.7  Med: 5.34 Max: 21.42
Current: 10.02
1.7
21.42
Quick Ratio 9.47
CRDC's Quick Ratio is ranked higher than
96% of the 185 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.60 vs. CRDC: 9.47 )
Ranked among companies with meaningful Quick Ratio only.
CRDC' s 10-Year Quick Ratio Range
Min: 1.26  Med: 5.05 Max: 20.95
Current: 9.47
1.26
20.95
Days Inventory 100.16
CRDC's Days Inventory is ranked higher than
68% of the 183 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 128.59 vs. CRDC: 100.16 )
Ranked among companies with meaningful Days Inventory only.
CRDC' s 10-Year Days Inventory Range
Min: 40.75  Med: 99.52 Max: 149.78
Current: 100.16
40.75
149.78
Days Sales Outstanding 44.06
CRDC's Days Sales Outstanding is ranked higher than
83% of the 161 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 63.01 vs. CRDC: 44.06 )
Ranked among companies with meaningful Days Sales Outstanding only.
CRDC' s 10-Year Days Sales Outstanding Range
Min: 9.01  Med: 29.65 Max: 82.52
Current: 44.06
9.01
82.52

Valuation & Return

vs
industry
vs
history
Price/Net Cash 1.79
CRDC's Price/Net Cash is ranked higher than
90% of the 42 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 12.72 vs. CRDC: 1.79 )
Ranked among companies with meaningful Price/Net Cash only.
CRDC' s 10-Year Price/Net Cash Range
Min: 2.52  Med: 7.67 Max: 107.5
Current: 1.79
2.52
107.5
Price/Net Current Asset Value 11.33
CRDC's Price/Net Current Asset Value is ranked lower than
67% of the 112 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.89 vs. CRDC: 11.33 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
CRDC' s 10-Year Price/Net Current Asset Value Range
Min: 1.99  Med: 7.01 Max: 48.75
Current: 11.33
1.99
48.75
Price/Tangible Book 3.78
CRDC's Price/Tangible Book is ranked higher than
55% of the 157 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.27 vs. CRDC: 3.78 )
Ranked among companies with meaningful Price/Tangible Book only.
CRDC' s 10-Year Price/Tangible Book Range
Min: 1.68  Med: 5.26 Max: 14.33
Current: 3.78
1.68
14.33
Price/Median PS Value 0.62
CRDC's Price/Median PS Value is ranked higher than
83% of the 166 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.15 vs. CRDC: 0.62 )
Ranked among companies with meaningful Price/Median PS Value only.
CRDC' s 10-Year Price/Median PS Value Range
Min: 0.17  Med: 1.01 Max: 1.94
Current: 0.62
0.17
1.94
Earnings Yield (Greenblatt) (%) -77.26
CRDC's Earnings Yield (Greenblatt) (%) is ranked lower than
98% of the 184 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.90 vs. CRDC: -77.26 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
CRDC' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -82.8  Med: 0.00 Max: 0
Current: -77.26
-82.8
0

Analyst Estimate

Jun15 Jun16 Jun17 Jun18
Revenue(Mil) 3 3 6 17
EPS($) -0.21 -0.16 -0.19 -0.14
EPS without NRI($) -0.21 -0.16 -0.19 -0.14

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare:WST, BAX, COV, TMO, COO » details
Traded in other countries:C5V.Germany,
Cardica Inc was incorporated in Delaware in October 1997 as Vascular Innovations, Inc. and changed its name to Cardica, Inc. in November 2001. The Company designs, manufactures and markets proprietary automated anastomotic systems used by cardiac surgeons to perform coronary bypass surgery. It is developing the MicroCutter XCHANGE 30, a cartridge-based microcutter device with a 5-millimeter shaft diameter, designed to be used in a variety of procedures, including bariatric, colorectal, thoracic and general surgery. The Company's C-Port Distal Anastomosis Systems, or C-Port systems, are sold in the United States and Europe. The C-Port systems are used to perform a distal anastomosis, which is the connection between a bypass graft vessel and the target coronary artery. It currently markets three proprietary products to perform anastomoses, the C-Port xA system, the C-Port Flex A system and the PAS-Port system. The C-Port systems automate a distal anastomosis between the graft vessel and target artery. The C-Port xA system was developed to use veins and arteries as the bypass graft vessel and received 510(k) clearance in November 2006. A new generation of the C-Port xA system, the C-Port Flex A system, designed to further enable minimally invasive CABG surgery, received 510(k) clearance in March 2007. The PAS-Port system automates the performance of a proximal anastomosis between a graft vessel, typically a saphenous vein, and the aorta. The PAS-Port system received 510(k) clearance in September 2008 following successful completion of a prospective, international, randomized study. The Company's main competitors include Ethicon Endo-Surgery, part of Johnson & Johnson, and Covidien. The FDA and other regulatory bodies extensively regulate the research, development, manufacture, labeling, distribution and marketing of its products.
» More Articles for CRDC

Headlines

Articles On GuruFocus.com
comment on CRDC Mar 23 2013 
CARDICA, INC. Reports Operating Results (10-Q) Feb 11 2011 
CARDICA, INC. Reports Operating Results (10-Q) Nov 15 2010 
CARDICA, INC. Reports Operating Results (10-Q) May 17 2010 
Weekly CFO Buy Highlight: CARDICA, NewBridge Bancorp, WESCO International, PrivateBancorp Inc., Syno Nov 07 2009 
CARDICA, INC. Reports Operating Results (10-Q) Nov 06 2009 
CARDICA, INC. (CRDC) CFO Robert Y Iv Newell buys 16,000 Shares Nov 04 2009 
Weekly CFO Buy Highlights: Cardica, Inc. (CRDC), American International Industries Inc (AMIN) Oct 10 2009 
CARDICA, INC. (CRDC) CEO Bernard A Hausen buys 19,960 Shares Oct 02 2009 
CARDICA, INC. (CRDC) CFO Robert Y Iv Newell buys 11,976 Shares Oct 02 2009 

More From Other Websites
CARDICA INC Files SEC form 8-K, Regulation FD Disclosure Aug 26 2015
Edited Transcript of CRDC earnings conference call or presentation 6-Aug-15 8:30pm GMT Aug 20 2015
Cardica Inc Earnings Call scheduled for 4:30 pm ET today Aug 06 2015
CARDICA INC Files SEC form 8-K, Results of Operations and Financial Condition, Change in Directors... Aug 06 2015
Cardica Announces Fiscal 2015 Fourth Quarter And Full Year Financial Results Aug 06 2015
Cardica Announces Leadership Transition Aug 06 2015
Q4 2015 Cardica Inc Earnings Release - After Market Close Aug 06 2015
Four Medical Picks With Healthy Earnings Outlooks Aug 04 2015
Cardica To Announce Fiscal 2015 Fourth Quarter Financial Results On Thursday, August 6, 2015 Jul 27 2015
CARDICA INC Files SEC form 8-K, Change in Directors or Principal Officers Jul 24 2015
Edited Transcript of CRDC earnings conference call or presentation 6-May-15 8:30pm GMT Jun 25 2015
CARDICA INC Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule... Jun 18 2015
CARDICA INC Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule... Jun 12 2015
CARDICA INC Financials May 22 2015
CARDICA INC Files SEC form 8-K, Change in Directors or Principal Officers May 21 2015
Cardica Announces New Employment Inducement Grant May 21 2015
5 Stocks Under $10 Set to Soar May 14 2015
CARDICA INC Files SEC form 10-Q, Quarterly Report May 12 2015
Cardica Inc Earnings Call scheduled for 4:30 pm ET today May 06 2015
CARDICA INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... May 06 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK